Clinical Trials Sponsored by Ferring Pharmaceuticals

Total 20925 results

CSL Behring

Completed

Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules

Primary Immune Deficiency | Secondary Immune Deficiency

Canada
Derming SRL

Completed

Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo

Hypertrichosis

Italy
CSL Behring

Completed

A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment

Acute Myocardial Infarction

Germany, United Kingdom
Derming SRL

Completed

Face Photoaging: Efficacy and Tolerance Evaluation of an Intradermal Injective Treatment

Face Skin Photoaging
Derming SRL

Completed

Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment (ANTI-ACNE)

Acne

Italy
Herning Hospital

Completed

Moxibustion in a Randomized Trial for Version of Breech Position From Week 32

Presentation; Breech, With External Version Before Labor
CSL Behring

Completed

Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert

Hereditary Angioedema Types I and II

Bulgaria, Hungary, Poland, Romania
CSL Behring

Completed

Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.

Emphysema | Alpha 1-proteinase Inhibitor Deficiency

Australia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden
CSL Behring

Completed

A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B

Hemophilia B

Bulgaria, Israel
CSL Behring

Completed

Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency

Emphysema | Alpha1-proteinase Inhibitor Deficiency

Australia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
CSL Behring

Completed

Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)

Primary Immune Deficiency

Japan
CSL Behring

Completed

Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)

Primary Immunodeficiency (PID)

Poland, Germany, France, Romania, Spain, Sweden, Switzerland, United Kingdom
CSL Behring

Completed

Health Related Quality of Life of Youth and Young Adults With Hemophilia A

Hemophilia A

Canada
Derming SRL

Completed

Humectant Activity of a New Formulation of Gynomunal® Vaginalgel (GYNOMUNAL®)

Menopause | Vaginal Dryness

Italy
CSL Behring

Completed

A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)

Multifocal Motor Neuropathy (MMN)

Switzerland, Italy, United Kingdom
CSL Behring

Completed

A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor

Hereditary Angioedema Types I and II

Germany
CSL Behring

Completed

A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency

Factor XIII Deficiency

United States, Spain
CSL Behring

Completed

Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis

Cystic Fibrosis

Bulgaria, Hungary, Poland, United Kingdom
CSL Behring

Completed

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

Von Willebrand Disease

Canada
CSL Behring

Completed

Retrospective Chart Review of Subcutaneous IgG Use in Infants

Primary Immune Deficiency

United States
Herning Hospital

Completed

The Effect of Caffeine in Elderly Citizens

Healthy Elderly Citizens

Denmark
University Hospital, Clermont-Ferrand
Centre Jean Perrin; Inserm U1107 " Neuro-Dol ", Clermont-Ferrand, France; Klinikum...

Completed

Validation of the French Version of the Pain Sensitivity Questionnaire (PSQ-F)

Healthy Volunteers | Scheduled Surgery

France
Lee's Pharmaceutical Limited
Powder (Guangzhou) Pharmaceuticals Limited; Powder Pharmaceuticals (HK) Co....

Not yet recruiting

A Study of the Continuous Glucose Monitoring System for Home Use in Patients With Diabetes

Diabetes
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Memorial Sloan Kettering Cancer Center
Ferring Pharmaceuticals; University of Michigan; University of Texas Southwestern...

Completed

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Prostate Cancer

United States
CSL Behring

Not yet recruiting

Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy

Hemophilia B
CSL Behring

Recruiting

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B (IX-TEND 4001)

Hemophilia B

United States
CSL Behring

Recruiting

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Complement Deficiencies

Australia
CSL Behring

Recruiting

Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )

Traumatic Injury

United States, United Kingdom, Australia
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
CSL Behring

Active, not recruiting

Register of Patients With haEmophilia A tReated With Afstyla® (OPERA)

Haemophilia A

France
CSL Behring

Completed

CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States, Canada, United Kingdom, Australia, Germany, Poland, Belgium, Austria, Denmark, Italy, Spain
CSL Behring

Completed

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis

Australia, Germany, Poland, Italy, United Kingdom
CSL Behring

Completed

Dose Confirmation Trial of AAV5-hFIXco-Padua

Hemophilia B

United States
CSL Behring

Completed

Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease

Sickle Cell Disease

United States, United Kingdom, Netherlands
CSL Behring

Completed

Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis

Hidradenitis Suppurativa | Palmoplantar Pustulosis

Denmark, Australia, Germany
CSL Behring

Completed

A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects

Healthy Participants

United States
CSL Behring

Terminated

Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects

Coronavirus Disease 2019 (COVID-19)

Australia
CSL Behring

Terminated

CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease

Anemia, Sickle Cell

United States
CSL Behring

Completed

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

Italy, United States, France, Argentina, Mexico, Japan, Canada, Hungary, South Africa
CSL Behring

Terminated

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Oral Mucositis

United States, Canada, Australia, Germany, Italy, Austria
CSL Behring

Terminated

Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) (ALD518-010)

Acute GvHD

United States
CSL Behring

Completed

A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

Hereditary Angioedema Types I and II

United States, Spain, Australia, Canada, Czechia, Hungary, Israel, Italy, Romania, United Kingdom
Herning Hospital

Completed

Detection of Adenomas in Screening Colonoscopy

Adenoma Colon

Denmark
CSL Behring

Withdrawn

Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)

Diffuse Cutaneous Systemic Sclerosis

Belgium, United States, Italy, Spain, France, Germany, United Kingdom, Argentina, Australia, Canada, Mexico, Poland, Switzerland
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis (ALD518-003)

Arthritis, Rheumatoid

Russian Federation, Serbia, Georgia, Canada, India, Poland
CSL Behring

Completed

Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia

Fatigue | NSCLC | Cachexia

Canada, Australia, Russian Federation, Georgia, Serbia, India, New Zealand, Poland, Romania
Derming SRL

Completed

Efficacy and Tolerance Evaluation of an Injective Treatment for the Area Around the Eyes

Under-eyes Dark Circles

Italy
Herning Hospital

Unknown

Robotic-assisted Hysterectomy: Single- vs. Multi-port Laparoscopic Access

Pain | Wound | Activity, Motor

Denmark
Derming SRL

Completed

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Malar and Sub-malar Volume Deficiency

Italy

3

Subscribe